Dosimetry of [ 177 Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial
Journal of Nuclear Medicine · 2025
DOI: 10.2967/jnumed.124.268903 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Nuclear Medicine, 2025. Verfasst von Lisa Bodei und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York; bodeil@mskcc.org. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Organometallic Compounds, Octreotide. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York; bodeil@mskcc.org.
- Radiation Research Unit, Istituto Europeo di Oncologia, IRCCS, Milan, Italy.
- Medical Physics Unit, Istituto Europeo di Oncologia, IRCCS, Milan, Italy.
- Division of Molecular Imaging and Therapy, Oregon Health and Science University, Portland, Oregon.
- Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany.
- Nuclear Medicine, University Hospitals Leuven, Leuven, Belgium.
Förderung
- NCI NIH HHS
Zitieren
APA
Bodei, L., Cremonesi, M., Ferrari, M., Mittra, E. S., Kulkarni, H. R., Deroose, C. M., Srirajaskanthan, R., Ramage, J., Grana, C. M., Botta, F., Weber, M. M., Miederer, M., Reddy, R., Chicco, D., Mariani, M. F., Demange, A., Erion, J. L., Gericke, G., & Krenning, E. (2025). Dosimetry of [ 177 Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.124.268903
Vancouver
Bodei L, Cremonesi M, Ferrari M, Mittra ES, Kulkarni HR, Deroose CM, et al. Dosimetry of [ 177 Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial. Journal of Nuclear Medicine. 2025. doi:10.2967/jnumed.124.268903
BibTeX
@article{Bodei2025,
author = {Bodei, Lisa and Cremonesi, Marta and Ferrari, Mahila and Mittra, Erik S and Kulkarni, Harshad R and Deroose, Christophe M and Srirajaskanthan, Rajaventhan and Ramage, John and Grana, Chiara Maria and Botta, Francesca and Weber, Matthias M and Miederer, Matthias and Reddy, Ryan and Chicco, Daniela and Mariani, Maurizio F and Demange, Arnaud and Erion, Jack L and Gericke, Germo and Krenning, Eric},
title = {Dosimetry of [ 177 Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial},
journal = {Journal of Nuclear Medicine},
year = {2025},
doi = {10.2967/jnumed.124.268903}
}
EUVIMED